Blood And Tears in Alzheimer's Disease (BAT-AD)

Danish Dementia Research Centre

Status: Enrolling

Conditions: Neurodegenerative Diseases

Study type: Observational

Funder types: NETWORK

Identifiers

NCT06567431

H-23078392

Details and patient eligibility

About

This study aims to investigate whether biomarkers of Alzheimer's disease can be found in tearfluid, as well as dried bloodspots in patients with Alzheimer's disease, other dementia diagnoses compared to controls.

Full description

Participants under investigation of a neurodegenerative disease who have a planned lumbar puncture in the Memory clinic will be invited to this study. On the same day of the lumbar puncture, tear fluid and dry blod spots will be collected.

Tear fluid is collected using Shirmer's test. Dried blood spots are obtained by a small prick in the finger with a lancet. The blood droplet is transferred onto a special piece of filter paper, where it dries.

As a sub-study, participants who have provided written consent specifically for this purpose will repeat the test with dried blood spots at home one week after participating in the study. The samples are submitted to the Memory Clinic at the participant's next scheduled appointment.

Tear fluid, dried blood spots, as well as blood and cerebrospinal fluid will be examined for AD-related pathology.

Enrollment: 600 estimated patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Inclusion criteria for patients:

• Lumbar puncture with CSF avaiable for analysis
• Diagnosis of Alzheimer's disease, Dementia with Lewy Bodies (DLB), Frontotemporal dementia (FTD), vascular dementia (VaD) or Normal pressure hydrocephalus (NPH)
• Of legal age.

Inclusion criteria for controls:

• Lumbar puncture with CSF avaiable for analysis
• No neurological disease.
• Of legal age.

Exclusion criteria

• No lumbar puncture
• Clinically assessed as unfit to participate in the project.

Trial design

600 participants in 3 patient groups

Alzheimer's disease

Description:

Patients diagnosed with Alzheimer's disease (AD), either MCI, mild or moderate dementia.

Cognitive impairment due to non-Alzheimer's disease

Description:

Patients diagnosed with one of the following dementia disorders: Dementia with Lewy Bodies (DLB), Frontotemporal dementia (FTD), vascular dementia (VaD) and Normal pressure hydrocephalus (NPH).

Controls

Description:

Patients who have undergone a diagnostic work-up in a memory clinic, but no neurodegenerative or other neurological disease was found, serve as control group.